Radiosensitization by BRAF inhibitor therapy--mechanism and frequency of toxicity in melanoma patients
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Radiosensitization by BRAF inhibitor therapy--mechanism and frequency of toxicity in melanoma patients
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 26, Issue 6, Pages 1238-1244
Publisher
Oxford University Press (OUP)
Online
2015-03-12
DOI
10.1093/annonc/mdv139
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cutis Verticis Gyrata in Association With Vemurafenib and Whole-Brain Radiotherapy
- (2014) James J. Harding et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response
- (2014) Laura Ridolfi et al. Journal of Translational Medicine
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib
- (2014) Andrea Forschner et al. MELANOMA RESEARCH
- Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia
- (2014) Nina Lang et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy
- (2014) Ricarda Merten et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
- (2013) Reinhard Dummer et al. EUROPEAN JOURNAL OF CANCER
- Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas
- (2013) Tina Dasgupta et al. INVESTIGATIONAL NEW DRUGS
- Severe Liver and Skin Toxicity After Radiation and Vemurafenib in Metastatic Melanoma
- (2013) Christopher J. Anker et al. JOURNAL OF CLINICAL ONCOLOGY
- Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy
- (2013) Imke Satzger et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity
- (2013) Natalia Rompoti et al. JOURNAL OF CLINICAL ONCOLOGY
- Vemurafenib and radiation therapy in melanoma brain metastases
- (2013) Ashwatha Narayana et al. JOURNAL OF NEURO-ONCOLOGY
- Paradoxical oncogenesis: are all BRAF inhibitors equal?
- (2013) Alexander M. Menzies et al. Pigment Cell & Melanoma Research
- Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib
- (2013) B. Schulze et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Cutaneous effects of BRAF inhibitor therapy: a case series
- (2012) P. L. Mattei et al. ANNALS OF ONCOLOGY
- Melanoma brain metastasis: overview of current management and emerging targeted therapies
- (2012) Ekokobe Fonkem et al. Expert Review of Neurotherapeutics
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032
- (2011) Maria J. Sambade et al. RADIOTHERAPY AND ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now